{
    "clinical_study": {
        "@rank": "3124", 
        "arm_group": [
            {
                "arm_group_label": "Spiromax/ProAir", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Albuterol Spiromax\u00ae 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir\u00ae HFA 180 mcg"
            }, 
            {
                "arm_group_label": "ProAir/Spiromax", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of ProAir\u00ae HFA 180 mcg  followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax\u00ae 180 mcg"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to compare the pharmacokinetic (PK) profiles of\n      Albuterol Spiromax\u00ae and ProAir HFA after administration of a single inhaled dose of 180 mcg\n      albuterol base from each product."
        }, 
        "brief_title": "Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax\u00ae and ProAir\u00ae Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "This is a single center, open-label, 2-period crossover study. The study consists of a\n      screening visit followed by a treatment period comprising 2 treatment visits. The treatment\n      period visits will be separated by a 4 to 14-day washout period. Eligible patients will be\n      kept overnight prior to each treatment period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent/assent signed and dated by the patient and/or\n             parent/caregiver/legal guardian (as appropriate) before conducting any study-related\n             procedure.\n\n          2. Male or pre-menarchal female patient 4-11 years of age, inclusive, as of the\n             Screening Visit (SV)\n\n          3. Has a documented physician diagnosis of persistent asthma of a minimum of 3 months\n             duration that has been stable for at least 4 weeks prior to the SV. The asthma\n             diagnosis must be in accordance with the National Asthma Education and Prevention\n             Program Guidelines Expert Panel Report 3 (EPR3).\n\n          4. Forced expiratory volume in 1 second (FEV1) >80% predicted for age, height and gender\n             and race at the SV based on the pediatric population standards.\n\n          5. Any patient being treated with inhaled corticosteroids (ICS) must be on a lowdose\n             regimen (200 mcg or less of fluticasone propionate per day or equivalent), which has\n             been stable for at least 4 weeks prior to the SV and which is expected to be\n             maintained for the duration of the study\n\n          6. Has required less than 4 inhalations per week of a rescue bronchodilator (on average)\n             for the 4 weeks preceding the SV\n\n          7. Has the ability to withhold inhaled albuterol for at least 72 hours preceding each\n             Treatment Visit (TV).\n\n               -  Other criteria apply, including must weigh at least 45 pounds\n\n        Exclusion Criteria:\n\n          1. A known hypersensitivity to albuterol or any of the excipients in the inhaler\n             formulations (lactose, ethanol, etc.)\n\n          2. Participation (receiving study drug) in any investigational drug trial within the 30\n             days preceding the SV or planned participation in another investigational drug trial\n             at any time during this trial\n\n          3. History of severe milk protein allergy\n\n          4. Proneness to orthostatic dysregulation, syncope, or blackouts\n\n          5. History of a respiratory infection or disorder (including, but not limited to\n             bronchitis, pneumonia, acute or chronic sinusitis, otitis media, influenza) that has\n             not resolved within 2 weeks preceding the SV.\n\n          6. History of life-threatening asthma or that is defined for this protocol as an asthma\n             episode that required intubation and/or was associated with hypercapnea, respiratory\n             arrest or hypoxic seizures\n\n          7. Any asthma exacerbation requiring systemic corticosteroids within 3 months of the SV.\n             A patient must not have had any hospitalization for asthma within 6 months prior to\n             the SV.\n\n               -  Other criteria apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844401", 
            "org_study_id": "ABS-AS-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Spiromax/ProAir", 
                    "ProAir/Spiromax"
                ], 
                "description": "Albuterol Spiromax\u00ae 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose", 
                "intervention_name": "Albuterol Spiromax\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Spiromax\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Spiromax/ProAir", 
                    "ProAir/Spiromax"
                ], 
                "description": "ProAir\u00ae HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose", 
                "intervention_name": "ProAir\u00ae HFA", 
                "intervention_type": "Drug", 
                "other_name": "ProAir\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Albuterol", 
                "Procaterol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "persistent asthma", 
            "Albuterol Spiromax\u00ae", 
            "ProAir\u00ae HFA", 
            "Pediatric Patients", 
            "Phase 1"
        ], 
        "lastchanged_date": "November 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Costa Mesa", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Teva Investigational Site 10538"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax\u00ae and ProAir\u00ae HFA in Pediatric Patients With Persistent Asthma", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Blood samples for plasma albuterol concentration determination will be drawn 5 (\u00b12) minutes prior to dosing and at 30 (\u00b12), 60 (\u00b15), 120 (\u00b110), 360 (\u00b110), and 600 (\u00b110) minutes after the completion of dosing.", 
                "measure": "Area under the plasma albuterol concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "Time 0 to the last detectable plasma albuterol concentration measured up to 10 hours post-dose (AUC0-t)"
            }, 
            {
                "description": "Blood samples for plasma albuterol concentration determination will be drawn 5 (\u00b12) minutes prior to dosing and at 30 (\u00b12), 60 (\u00b15), 120 (\u00b110), 360 (\u00b110), and 600 (\u00b110) minutes after the completion of dosing.", 
                "measure": "Maximum observed plasma albuterol concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to up to 10 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Effects on vital signs (blood pressure, pulse rate) over 6 hours post-dosing", 
                "measure": "Pharmacodynamic Effect on Vital Signs", 
                "safety_issue": "No", 
                "time_frame": "From baseline to up to 6 hours post dose"
            }, 
            {
                "measure": "Summary of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 to end of Follow-up Visit (approximately 4 weeks)"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}